Accolade, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Accolade, Inc. Accolade, Inc. (Nasdaq: ACCD) provides personalized, technology-enabled healthcare solutions that help individuals navigate the healthcare system and workplace benefits primarily in the United States; its core offerings include a cloud-based intelligent platform supported by advocates and clinicians such as registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians; these encompass personalized advocacy and navigation services, medical opinion consultations connecting patients to condition-specific specialists for adult and pediatric care, virtual primary care and mental health support solutions, Accolade Care for telemedicine appointments and integrated therapy, Accolade Boost add-on offerings, and a Trusted Supplier Program integrating partners for diabetes, mental health, fertility, musculoskeletal (MSK), kidney disease, oncology, and medication management. The company serves self-insured employers, health plans, government entities, and their employees and families, targeting improved health outcomes, cost savings, and access to high-quality care through predictive AI-driven engagement, data aggregation from claims and interactions, and multimodal support channels including phone, app, and web; it operates with a focus on enterprise clients, supporting over 13.5 million members as of recent reports, and maintains deep integrations with provider, partner, and payer ecosystems. Founded in 2007 by Michael Cline and Bryan Sivak in Plymouth Meeting, Pennsylvania, and headquartered in Seattle, Washington, Accolade has evolved through key milestones including early enterprise contracts in 2010, Series D funding and leadership changes in 2015, and acquisitions of PlushCare for virtual care and 2nd.MD for expert opinions in 2021; in fiscal 2024, it reported revenue of approximately $415 million with expansions in value-based care models and point solutions. Most recently, in April 2025, Accolade completed its acquisition by Transcarent, Inc. for roughly $621 million at $7.03 per share in cash, transitioning to operate as a privately held subsidiary delisted from Nasdaq; this strategic merger integrates Transcarent's generative AI-powered WayFinding, comprehensive care experiences in cancer, surgery, weight health, and pharmacy benefits with Accolade's advocacy platform, aiming to create a unified "one place for health and care" with enhanced personalization, utilization, and cost reductions for over 1,400 employer and payer clients.
Vontier Earns Top Accolade at International Sustainability Awards
Scripps Cancer Center Leader Receives National Accolade
Defining Wellness Centers Names Bill Morrison Chief Financial Officer
CoinEx Wins Top Accolade for Cryptocurrency Exchange at International Business Magazine Awards 2025
TalkingParents Takes Home 11th Accolade For Support Network Initiative
The One Show Announces Historic Win: Klick Health Becomes First Health Agency to Ever Receive An Agency of the Year Accolade
Wellspring Launches Next-Gen Innovation Platform, Accolade Core
Pernod completes sale of wine portfolio to Accolade Wines owner
Digital health startup Transcarent takes Accolade private in $621 million deal
Transcarent Completes Merger With Accolade
Accolade Stockholders Approve Merger Between Accolade and Transcarent
Accolade Welcomes Oshi Health to Trusted Partner Ecosystem
Has Accolade (ACCD) Outpaced Other Business Services Stocks This Year?
ACCD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Accolade, Inc. Is Fair to Shareholders
Transcarent and Accolade Announce Expiration of Hart-Scott Rodino Waiting Period for Pending Merger Transaction
Accolade Expands Virtual Care to Medicare Beneficiaries Nationwide Through PlushCare Direct-to-Consumer Offering
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Accolade
Accolade (ACCD) Reports Q3 Loss, Lags Revenue Estimates
ACCOLADE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Accolade, Inc. - ACCD
Why Is Accolade Stock Trading Over 100% On Tuesday?